Abstract
Osteoporosis is a progressive skeletal disorder characterized by reduced bone mass and deterioration of bone tissue, leading to increased fracture risk, disability, and reduced quality of life. Despite the availability of several pharmacological interventions, variability in treatment response and long-term effectiveness remains a clinical concern, particularly in aging populations. The objective of this study is to examine the effectiveness of pharmacological interventions used in the management of osteoporosis and to evaluate their impact on bone mineral density, fracture prevention, and patient outcomes. A narrative review methodology was employed, analyzing recent clinical trials, systematic reviews, and meta-analyses focusing on major drug classes including bisphosphonates, selective estrogen receptor modulators (SERMs), denosumab, and parathyroid hormone analogs. Studies were selected based on relevance, recency, and clinical significance. The major findings indicate that bisphosphonates remain the first-line therapy due to their proven efficacy in reducing vertebral and non-vertebral fractures. Denosumab shows strong effectiveness in increasing bone mineral density, particularly in high-risk patients, while anabolic agents demonstrate superior outcomes in severe osteoporosis cases. However, long-term adherence, side effects, and cost constraints significantly influence treatment effectiveness. In conclusion, pharmacological interventions for osteoporosis are generally effective, but optimal outcomes depend on individualized treatment strategies and patient compliance. The study highlights the need for personalized medicine approaches and long-term monitoring to improve therapeutic success